STAT1 min read
STAT+: AstraZeneca Sues Arkansas Over The Role Of Pharmacies In A Federal Discount Drug Program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a federal discount program.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Arguments, A Merck Drug Approval, And More
U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.
STAT4 min read
STAT+: Pharmalittle: We’re Reading About Amgen Suing Colorado Over Drug Price Caps, Abortion Pills, And More
Amgen accused a Colorado board of violating the U.S. Constitution with its first-in-the-nation plan to cap the cost of a pricey prescription medicine.
STAT1 min read
Disparities In Donor Acceptance Rates Point To Need For More Equitable Heart Transplant Care
While access to donor hearts has increased, there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, a new study finds.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Novo Nordisk Deal, A Regeneron Setback, And More
Novo Nordisk agreed to acquire Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional cardiometabolic drug candidates.
STAT2 min read
Opinion: STAT+: Medical Devices Makers Are Trying To Take A Page From Uber’s Playbook
When it comes to device makers, regulators and payers should be on the lookout for Uber-like behavior — including aggressive marketing strategies.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Medicare And Obesity Drugs, FDA Syringe Warnings, And More
This morning in the Pharmalittle roundup: We're reading about Medicare and obesity drugs, FDA syringe warnings, and more.
STAT1 min read
STAT+: U.K. Health Officials And Researchers Try To Carve A Path For More Individualized Genetic Treatments
Researchers and government agencies in the U.K. are trying to figure out how to best advance individualized genetic treatments.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Medicare And Obesity Drugs, GSK Asthma Inhalers, And More
The Congressional Budget Office forecast that Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years.”
STAT1 min read
STAT+: New Gene Therapy, To Be Priced At $4.25 Million, Has Already Transformed Children’s Lives
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Europe’s Pharma Reform, Weight-loss Meds, And More
Weight-loss medications are not reaching the people who need them most, and white adults were more likely than Asian or Black adults to get them in a new study.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min readAddiction
STAT+: The Methadone Clinic Monopoly: Opioid Treatment Chains Backed By Private Equity Are Fighting Calls For Reform
Private equity’s surging interest in the methadone treatment industry adds a new layer to the fraught and fast-shifting debate over access to addiction medications.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CAR-T Drugs For Myeloma, CVS Rebate Credits, And More
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Liver-drug Approval, Pharma’s Positive Outlook, And More
The FDA granted accelerated approval for the first medicine developed specifically to treat a serious liver disease known as MASH.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About BIO Cutting Ties With WuXi, EU Pharma Rules, And More
The BIO industry trade group is cutting ties with China's WuXi in response to U.S. government scrutiny of the biotech and other Chinese companies.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amazon Delivering Zepbound, Hemophilia Treatments, And More
Amazon Pharmacy, which has sold prescription medicines online since 2020, will now handle home delivery of the anti-obesity therapy Zepbound.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT1 min read
Opinion: Good Health Care Price Transparency Rules Are At Risk If Congress Doesn’t Act
Health price transparency isn’t just about consumers — it’s also about designing employee health plans that benefit everyone.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Failed Schizophrenia Drug Trial, A Pfizer Cancer Drug, And More
Acadia Pharmaceuticals disclosed that Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy Approved For Heart Risks, An ALS Drug Puzzle, And More
The FDA approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage.
STAT1 min read
STAT+: IVF Doctors Demand Full Details On Fluid That Grows Embryos Amid CooperSurgical Lawsuits
Patients from all over the country are filing lawsuits against medical supply giant CooperSurgical, alleging that fluid the company sent to in vitro fertilization clinics destroyed their embryos. The fluid, called culture media, is filled with nutrie
STAT1 min read
Opinion: STAT+: It’s Time To Rethink Everything About Our Approach To Psychiatric Drug Development
Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Alzheimer’s Drug Adcomm, Amylyx ALS Drug Flop, And More
In a surprise, the FDA has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved.
STAT2 min read
STAT+: Eli Lilly’s Anti-vanity Ad Campaign For Oscars
Eli Lilly will be unveiling a new campaign during this weekend’s Oscar awards event, with a clear message: These drugs aren’t meant to be used for cosmetic reasons. "It matters…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Lilly Obesity-drug Ad, A $35 Cap On Inhalers, And More
Ahead of the Oscars and amid shortages, Lilly is running a new ad campaign urging consumers against vanity use of weight-loss drugs.
STAT1 min read
Opinion: Free Tuition Won’t Fix Medicine’s Diversity Problem Without Admissions Reform
A second New York medical school is going tuition-free in hopes of improving diversity. But more changes are needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About HIV Drug Resistance, March-in Rights, And More
The World Health Organization said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its clinical trials.
STAT1 min readAddiction
STAT+: Q&A: Nora Volkow On How To Get ‘At Least 50% Less People Dying’ From Opioid Overdose
"We’ve generated, in our country, a very different system for treating people that have problems with addiction, versus the health care system that treats everything else," says NIDA's Nora Volkow.
…Or Discover Something New